Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from ANI Pharmaceuticals Inc

3 Biotech Stocks Poised for May Surges

The use of advanced technologies, growing demand for personalized medicines, and rising investments in R&D are boosting the biotech industry’s prospects. Given this backdrop, investors could consider buying quality biotech stocks: Amgen (AMGN), Jazz Pharmaceuticals (JAZZ), and ANI Pharmaceuticals (ANIP). Read on.

StockNews.com · May 17, 2024

3 Biotech Stocks Gaining Altitude and Interest

This year, the biotech industry anticipates a resurgence with increased M&A, FDA approvals, and AI-driven innovations. Given the industry’s rosy prospects, biotech stocks BioMarin Pharmaceutical (BMRN), ANI Pharmaceuticals (ANIP), and Genmab A/S (GMAB), gaining significant altitude and interest, could be ideal buys. Read on.

StockNews.com · Apr 10, 2024

3 Biotech Stocks to Jumpstart Your Portfolio Gains

The biotech industry is poised for robust growth due to increasing demand for personalized treatments, rising prevalence of chronic diseases, heightened investments in R&D, and advancements in technology. Therefore, investors could consider buying fundamentally strong biotech stocks Innoviva (INVA), ANI Pharmaceuticals (ANIP), and United Therapeutics (UTHR). Read more.

StockNews.com · Mar 14, 2024

From analysis to the latest developments in health,
read the most diverse news in one place.

Biotech Stock Success: Top 3 Picks for Monthly Gains

Amid the dynamic biotech landscape, the sector is set to witness an upward trajectory fueled by consistent advancements. Therefore, it could be wise to buy fundamentally strong biotech stocks Protalix BioTherapeutics (PLX), Organogenesis Holdings (ORGO), and ANI Pharmaceuticals (ANIP) for monthly gains. Read more.

StockNews.com · Jan 31, 2024

3 Biotech Stocks to Buy to Help the Health of Your Portfolio

Amid the dynamic biotech landscape, the sector is set to witness substantial growth fueled by multiple advancements. Hence, fundamentally strong biotech stocks ANI Pharmaceuticals (ANIP), Exelixis (EXEL), and Entrada Therapeutics (TRDA) might be solid investments now. Read more….

StockNews.com · Nov 23, 2023

ANI Pharma Posts Mixed Bag Q4 Earnings, FY22 Sales Outlook Trails Street Consensus

ANI Pharmaceuticals Inc's (NASDAQ:ANIP) Q4 revenues were $60.9 million, +6.4% Y/Y, beating the consensus of $56.30 million. Net revenues for generic pharmaceutical products were $41.6 million, +8% primarily due to the Novitium acquisition and Q3 launch of Nebivolol, tempered by sales declines for Tolterodine and Vancomycin and lower average selling prices of…

Benzinga · Mar 15, 2022

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Jazz Pharmaceuticals plc

BioMarin Pharmaceutical Inc

United Therapeutics Corporation

19 stories

GMAB

18 stories

Entrada Therapeutics Inc

17 stories

Innoviva Inc

14 stories

Organogenesis Holdings Inc

14 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.